Please use this identifier to cite or link to this item:
Title: The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy
Authors: Fortes-Andrade, Tânia 
Almeida, Jani-Sofia 
Sousa, Luana Madalena 
Santos-Rosa, Manuel 
Freitas-Tavares, Paulo 
Casanova, José Manuel 
Rodrigues-Santos, Paulo 
Keywords: soft tissue sarcoma; natural killer cells; innate immunity; innate lymphoid cells; immunotherapy; immune checkpoint inhibitors; clinical trials
Issue Date: 31-Jul-2021
Publisher: MDPI
Project: POCI-01-0145- FEDER-007440 
Serial title, monograph or event: Cancers
Volume: 13
Issue: 15
Abstract: Soft-tissue sarcomas (STS) represent about 80% of sarcomas, and are a heterogeneous group of rare and malignant tumors. STS arise from mesenchymal tissues and can grow into structures such as adipose tissue, muscles, nervous tissue and blood vessels. Morphological evaluation has been the standard model for the diagnosis of sarcomas, and even in samples with similar characteristics, they present a diversity in cytogenetic and genetic sequence alterations, which further increases the diversity of sarcomas. This variety is one of the main challenges for the classification and understanding of STS patterns, as well as for their respective treatments, which further decreases patient survival (<5 years). Despite some studies, little is known about the immunological profile of STS. As for the immunological profile of STS in relation to NK cells, there is also a shortage of studies. Observations made in solid tumors show that the infiltration of NK cells in tumors is associated with a good prognosis of the disease. Notwithstanding the scarcity of studies to characterize NK cells, their receptors, and ligands in STS, it is noteworthy that the progression of these malignancies is associated with altered NK phenotypes. Despite the scarcity of information on the function of NK cells, their phenotypes and their regulatory pathways in STS, the findings of this study support the additional need to explore NK cell-based immunotherapy in STS further. Some clinical trials, very tentatively, are already underway. STS clinical trials are still the basis for adoptive NK-cell and cytokine-based therapy.
ISSN: 2072-6694
DOI: 10.3390/cancers13153865
Rights: openAccess
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais
I&D CIBB - Artigos em Revistas Internacionais

Show full item record

Page view(s)

checked on May 22, 2024


checked on May 22, 2024

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons